

FLEURY S.A.**Public Company****Corporate Taxpayer ID (CNPJ/MF) 60.840.055/0001-31****Company Registry (NIRE) 35.300.197.534****MATERIAL FACT**

Fleury S.A. ("Grupo Fleury" or "Company"), in compliance with the provisions of art. 157, §4 of the Brazilian Corporation Law and CVM Instruction No. 358/02, informs its shareholders and the market in general that, on this date, the Board of Directors informed the Company that Jeane Tsutsui, who had been exercising the position of Executive Director since 2012, takes on as the new Chief Executive Officer of the Company, replacing Carlos Marinelli, who leaves the position after 7 years at the leadership of the Company.

Carlos Marinelli joined Grupo Fleury in 2005 and developed a solid career in several positions, becoming Chief Executive Officer in 2014. Under his management, he led the Company to deliver significant results and value generation with consistent growth and strategic development in the direction of making it a reference in the construction of integrated solutions in the concept of the Healthcare Platform, as well as conducting a strategic acquisition process..

Jeane Tsutsui has been a member of the Company for 20 years and has also developed her career in a remarkable way, migrating her medical career to executive management in the last 14 years. Graduated in Medicine at Ribeirão Preto Medical School-USP, she did residency in Cardiology at Incor-USP. She has a doctorate in Cardiology, a postdoctoral degree at the University of Nebraska Medical Center and she is a professor at the USP School of Medicine. She holds an MBA in Knowledge, Innovation and Technology from FIA and has completed management formation at Harvard Business School, Wharton and Sloan School of Management - MIT. Since 2018, Jeane has been responsible for business management.

So far, Grupo Fleury has been making strategic acquisitions that complement its portfolio and integrating services and solutions into its Healthcare Platform and has presented robust results that strengthen its position as one of the most respected healthcare institutions in the country. With this movement, we started a new cycle of

accelerating growth, digital/technological transformation of the Company, with the ambition to build a sustainable healthcare ecosystem, in line with the best ESG practices.

The Board of Directors expresses its highest thanks to Carlos Marinelli for the outstanding leadership he exercised over his 16 years at the Company, strengthening our purpose, making it an exponent in management excellence and always expanding our notoriety as a technical and medical reference. The transition in management will be gradual and will take place until the end of April.

We wish Jeane Tsutsui to be very successful in this stage of her career at Grupo Fleury, leading the Company into the future and further strengthening her role in the healthcare market.

São Paulo, April 7th, 2021

FERNANDO AUGUSTO RODRIGUES LEÃO FILHO

Chief Financial and Investor Relations Officer